Michael R. Mcalevey Buys 1,110 Shares of HCA Healthcare, Inc. (NYSE:HCA) Stock

HCA Healthcare, Inc. (NYSE:HCAGet Rating) SVP Michael R. Mcalevey purchased 1,110 shares of the firm’s stock in a transaction on Friday, April 29th. The stock was bought at an average price of $218.56 per share, with a total value of $242,601.60. Following the completion of the purchase, the senior vice president now owns 1,110 shares of the company’s stock, valued at $242,601.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

HCA Healthcare stock opened at $216.30 on Wednesday. The company has a debt-to-equity ratio of 87.46, a quick ratio of 1.24 and a current ratio of 1.43. HCA Healthcare, Inc. has a 52 week low of $199.76 and a 52 week high of $279.02. The stock has a market capitalization of $65.33 billion, a P/E ratio of 10.18, a price-to-earnings-growth ratio of 1.29 and a beta of 1.60. The stock has a fifty day moving average of $252.11 and a 200-day moving average of $247.55.

HCA Healthcare (NYSE:HCAGet Rating) last posted its quarterly earnings results on Friday, April 22nd. The company reported $4.12 EPS for the quarter, missing analysts’ consensus estimates of $4.25 by ($0.13). HCA Healthcare had a return on equity of 405.72% and a net margin of 11.40%. The business had revenue of $14.95 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the firm posted $4.14 EPS. HCA Healthcare’s quarterly revenue was up 6.9% on a year-over-year basis. On average, research analysts forecast that HCA Healthcare, Inc. will post 17.15 earnings per share for the current year.

HCA Healthcare declared that its Board of Directors has initiated a share repurchase program on Thursday, January 27th that permits the company to repurchase $8.00 billion in shares. This repurchase authorization permits the company to reacquire up to 10.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 16th will be issued a $0.56 dividend. The ex-dividend date of this dividend is Wednesday, June 15th. This represents a $2.24 dividend on an annualized basis and a yield of 1.04%. HCA Healthcare’s payout ratio is presently 10.54%.

Institutional investors and hedge funds have recently modified their holdings of the business. Equitec Proprietary Markets LLC acquired a new position in HCA Healthcare in the 4th quarter worth about $26,000. Baltimore Washington Financial Advisors Inc. acquired a new position in HCA Healthcare in the 4th quarter worth about $26,000. GoalVest Advisory LLC bought a new stake in shares of HCA Healthcare in the 1st quarter valued at about $26,000. Amplius Wealth Advisors LLC bought a new stake in shares of HCA Healthcare in the 4th quarter valued at about $27,000. Finally, PYA Waltman Capital LLC bought a new stake in shares of HCA Healthcare in the 4th quarter valued at about $31,000. 67.87% of the stock is owned by institutional investors and hedge funds.

HCA has been the subject of several research analyst reports. StockNews.com downgraded HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 25th. Raymond James reduced their target price on HCA Healthcare from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Tuesday, April 26th. Wells Fargo & Company reduced their target price on HCA Healthcare from $267.00 to $227.00 and set an “equal weight” rating for the company in a research note on Monday, April 25th. Royal Bank of Canada reduced their price target on HCA Healthcare from $291.00 to $267.00 and set an “outperform” rating for the company in a research note on Monday, April 25th. Finally, Mizuho reduced their price target on HCA Healthcare from $290.00 to $260.00 in a research note on Tuesday. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $259.27.

HCA Healthcare Company Profile (Get Rating)

HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

See Also

Insider Buying and Selling by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.